READ. SCROLL. LISTEN.

Unbiased headlines. Facts, not spin.

Unbiased Headlines is an independently owned news organization. We bring you the facts, not opinions, written fresh from 110+ named sources. Sources linked so you can verify it yourself.

← Back to headlines

FDA Will Miss Nov. 22 Decision Date on Savara's Lung Drug and Has Set No New Date

FDA Will Miss Nov. 22 Decision Date on Savara's Lung Drug and Has Set No New Date
The FDA told Savara it will not act on molgramostim, an inhaled drug for autoimmune PAP, by its Sunday, Nov. 22 goal date, and gave no replacement date. The application has not been rejected, but patients with no approved treatment and a company with one clinical-stage asset are left waiting on an open-ended review.

The FDA will not meet tomorrow's deadline, Sunday, Nov. 22, to decide on Savara's inhaled drug for a rare lung disease, and it has not said when it will.

Savara (Nasdaq: SVRA) announced Friday, Nov. 20, that the agency told it the review of its biologics license application for molgramostim is ongoing and that no revised action date has been provided. The FDA has not issued a complete response letter, the formal rejection that normally closes a review cycle.

What Savara and the FDA have said

The company did not say why the agency needs more time. It did not say whether the FDA has asked for more data or flagged problems.

"We appreciate the FDA's continued efforts on our application and look forward to working closely with the agency to complete its review," said Matt Pauls, Savara's chair and CEO.

This is the second slip. On April 15, the FDA pushed the original goal date back three months after deciding that Savara's responses to information requests amounted to a major amendment to the application. Savara said at the time that the extension was not tied to safety, efficacy or manufacturing issues.

The stock

Savara shares fell about 18% at Friday's open to $4.26, from a $5.21 close Thursday. Reuters reported the stock down 16% in premarket trading. The shares hit a 52-week low and are down more than 29% in 2026, according to Stocktwits.

Molgramostim is Savara's only clinical-stage asset. The company had roughly $173 million in cash and short-term investments as of June 30, and it has not updated its launch outlook or quantified any financial impact from the delay.

The patients

Autoimmune pulmonary alveolar proteinosis, or aPAP, is a disease in which surfactant builds up in the lungs' air sacs and impairs oxygen exchange. Estimates put the U.S. patient count at 2,000 to 8,000.

No FDA-approved treatment exists. The standard option is whole-lung lavage, an invasive procedure under general anesthesia in which the lungs are repeatedly washed.

If approved, molgramostim would be the first approved therapy for the condition.

The data behind the application

The application rests on the Phase 3 IMPALA-2 trial of 164 adults. Molgramostim at 300 µg daily met its primary endpoint, a gain in hemoglobin-adjusted lung diffusing capacity (DLCO) over placebo at Week 24. The treatment difference was 6.0 percentage points (p=0.0007). The gap was 6.9 points at Week 48 (p=0.0008).

The drug carries FDA Priority Review, Breakthrough Therapy, Fast Track and Orphan Drug designations.

Analysts see a delay, not a no

Jefferies analysts called missed PDUFA dates rare, and noted the FDA has had 11 months with the data package. They wrote that Savara has no color on why the agency needs more time and that they expect stock volatility.

The firm said a postponement instead of a rejection letter could point to "potential FDA bandwidth issues." It also weighed manufacturing as a possible factor. The FDA previously refused to review a 2025 application over chemistry, manufacturing and controls concerns, and Savara later resolved those deficiencies.

Jefferies still holds "high confidence" in approval, citing "compelling" Phase 3 data and durability in an open-label extension. It said a delay could still leave room for a U.S. launch in early 2027.

Guggenheim analysts wrote that they have "consistently believed that the Molbreevi clinical data is sufficient for FDA approval" and that the company has taken the proper steps on manufacturing questions.

Those are analyst views. The FDA has offered no explanation of its own.

A different outcome on the same date

Capricor Therapeutics' deramiocel, a cell therapy for Duchenne muscular dystrophy, shared the Nov. 22 goal date. On Friday, Capricor said the FDA issued a complete response letter citing data-integrity problems, including unauthorized changes to statistical analyses and trial-blinding violations. Reuters reported its shares fell more than 70% in after-hours trading.

Savara's application has drawn no such finding. The two situations are separate, and no one has linked them.

The wider backdrop

The delay lands as investment bank Cassel Salpeter questions whether FDA layoffs, disrupted research funding and higher tariffs are hurting smaller biotechs most. The bank did not tie that argument to the Savara decision.

PDUFA dates are the schedule the agency commits to in exchange for the fees drugmakers pay. When the FDA misses one with no new date, a small company with a single asset cannot plan hiring, financing or a launch.

The open question is how long the review runs. Savara has not said when it expects to hear from the FDA, and the agency has not committed to a date.

Sources used for this briefing

7 links from 7 independent newsrooms (syndicated copies of the same report count once)

These are the sources it draws on, linked so you can verify.

center
KELO-TVFDA to miss deadline on Savara’s rare lung disease drug approval
right
Epoch TimesFDA Declines Approval of China-Developed Lung Cancer Drug After Survival Goal Missed
unknown
Tech TimesFDA Misses Sunday Savara Decision Date on Inhaled Lung Drug: No Rejection, No New Date - Tech Times
unknown
PharmacallyFDA Delays Decision on Savara’s Molgramostim for Autoimmune PAP
unknown
BigGo FinanceSavara Shares Drop 18% as FDA Misses Molbreevi Action Date With No Replacement Deadline — BigGo Finance
unknown
BioSpaceFDA will miss rare decision deadline for Savara candidate after three-month delay
unknown
investors.savarapharmaSavara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date